Cyclic Peptide Ligands for Stable Somatostatin Receptor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current synthetic Somatostatin analogues, such as Octreotide and Lanreotide, have limited receptor specificity and stability, which can lead to ineffective treatment and side effects due to varying distribution of Somatostatin receptors in cells, and there is a need for therapeutically-active, stable, and receptor-specific somatostatin analogues.
Innovation Solution
Development of Somatostatin receptor ligands with specific peptide moieties, including cyclic peptides covalently bonded with active agents like nanoparticles, imaging moieties, or therapeutic agents, which selectively bind to Somatostatin Receptors, enhancing receptor specificity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current synthetic Somatostatin analogues (Octreotide and Lanreotide) are used, then high-affinity binding to SSTR2 is achieved, but receptor specificity is limited and stability is reduced
Solution Approach 1:
The patent applies composite materials by combining the cyclic peptide moiety (providing receptor binding specificity) with nanoparticle active agent moieties (providing enhanced stability and therapeutic function). This creates a hybrid molecule that integrates the advantages of both organic peptide structures and inorganic nanoparticle properties, achieving improved receptor specificity while maintaining enhanced stability.
Solution Approach 2:
The patent implements the nested doll principle by covalently bonding the cyclic peptide moiety to nanoparticle active agent moieties, creating a hierarchical structure where the peptide is embedded on the nanoparticle surface. This nested configuration allows the peptide to maintain its binding specificity while the nanoparticle core provides structural stability and protects the peptide from degradation.
2Reliability
If synthetic Somatostatin analogues are used, then therapeutic activity is achieved, but side effects occur due to varying distribution of Somatostatin receptors
Solution Approach 1:
The patent applies local quality by designing the ligand to have heterogeneous composition with multiple functional moieties distributed at different locations. The cyclic peptide portion targets specific receptor subtypes locally, while nanoparticle moieties provide localized therapeutic action. This spatial differentiation of function reduces off-target effects and minimizes side effects by concentrating activity where needed.
Solution Approach 2:
The patent implements parameter changes by modifying the molecular parameters of Somatostatin analogues through conjugation with nanoparticle moieties. This changes the physical and chemical parameters of the molecule, including size, stability, and binding characteristics, thereby improving therapeutic effectiveness while reducing side effects associated with conventional analogues.
3Reliability
If conventional Somatostatin analogues are used, then binding to SSTR2 is achieved, but binding affinity to various SSTR subtypes is insufficient
Solution Approach 1:
The patent applies universality by designing a multi-functional ligand that can bind to multiple Somatostatin receptor subtypes (SSTR1-SSTR5). The cyclic peptide moiety is engineered with specific amino acid sequences that recognize common features across different SSTR subtypes, while the nanoparticle moieties provide additional interaction sites. This multi-functional design enables the ligand to adapt to varying receptor distributions in different tissues and pathological conditions.
Data Source
AI summary
Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.